AxoGen to Participate at AAHS ASPN ASRM Joint 2017

ALACHUA, Fla., Jan. 03, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the joint 2017 Meeting of the American Association for Hand Surgery, American Society for Peripheral Nerve and the American Society for Reconstructive Microsurgery taking place in Waikoloa, Hawaii from January 10 - 17, 2017.

AxoGen will host an educational symposium, "The Evolving Algorithm in Nerve Repair: An Interactive Case Based Exercise with the Experts", which will focus on current concepts in peripheral nerve repair followed by a hands-on experience with innovative materials in peripheral nerve repair.  A panel of experts will discuss recent updates to peer reviewed literature and how their nerve repair algorithm is evolving through the introduction of new technologies.  The interactive session will uncover areas of consensus and debate in the rapidly evolving area of nerve repair.  AxoGen’s full portfolio of nerve repair and assessment products will be featured at Booth #39.

“We are excited to be hosting a symposium focused on peripheral nerve repair and provide an interactive experience for surgeons,” stated Karen Zaderej, AxoGen’s President and Chief Executive Officer. “AxoGen is committed to raising awareness on the repair options for different nerve injuries and we are pleased to support educational efforts at this joint meeting which attracts a large number of surgeons representing a variety of specialties”.

AxoGen symposium details for the AAHS ASPN ASRM Meeting are as follows:

Thursday, January 12, 12:30 pm – 4 pm "The Evolving Algorithm in Nerve Repair: An Interactive Case Based Exercise with the Experts" Invited Faculty: Gregory Buncke, MD, FACS, Ivan Ducic, MD, PhD, Peter Evans, MD, PhD, Amy Moore, MD, FACS, Ian Valerio, MD, MBA, FACS

About AAHS ASPN ASRM Joint 2017 Annual Meeting The American Association for Hand Surgery represents a diverse but cohesive mix of highly respected professionals working in all disciplines of hand surgery and hand therapy. Members include orthopedic surgeons, plastic surgeons, general surgeons, microsurgeons, hand therapists, nurses, and basic scientists from the United States, Canada, and many other countries around the world. For more information, please visit: www.handsurgery.org .

The American Society for Peripheral Nerve was established to stimulate and encourage study and research in the field of neural regeneration, to provide a forum for the presentation of the latest research and relevant clinical information and to serve as a unifying authority on all areas of neural regeneration and restorative neuroscience. For more information, please visit: www.peripheralnerve.org

The American Society for Reconstructive Microsurgery was established to promote, encourage, foster, and advance the art and science of microsurgery and complex reconstruction and to establish a forum for teaching, research and free discussion of reconstructive microsurgical methods and principles. For more information, please visit: www.microsurg.org

About AxoGen, Inc. AxoGen Inc. (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen’s portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive™ Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. Along with these core surgical products, AxoGen also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties which may cause actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include the risks associated with the actual use of proceeds from the offering and the discretion of AxoGen’s management to determine how to use such proceeds, as well as the risks and uncertainties that could affect the Company's business and financial results described in the final prospectus supplement and registration statement referenced above, as well as the Company’s other filings with the SEC, including, without limitation, under the caption "Risk Factors." Forward-looking statements relate only to events as of the date on which the statements are made, and the Company undertakes no obligation to publicly update or review any forward-looking statement.

Contacts: AxoGen, Inc. Peter J. Mariani, Chief Financial Officer 386.462.6856 InvestorRelations@AxoGenInc.com The Trout Group – Investor Relations                                              Brian Korb 646.378.2923 bkorb@troutgroup.com